Your email has been successfully added to our mailing list.

×
0 0 0 0 0.111111111111111 0.0890000000000001 0.079888888888889 0.0667777777777778
Stock impact report

Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Fai...

Onconova Therapeutics, Inc. (ONTX) 
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.onconova.com/investor-overview
Company Research Source: GlobeNewswire
First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of the novel combination therapy in higher risk patients with Myelodysplastic Syndromes (MDS)Study demonstrates elimination of grade 3 or grade 4 urinary adverse events after implementation of mitigation strategies NEWTOWN, Pa., March 26, 2018 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, presented promising new clinical safety data from the expansion phase of a Phase 2 clinical trial at the Bone Marrow Failure Disease Scientific Symposium, held in Rockville, Maryland, on March 22-23, 2018. Oral rigosertib has been developed as a single agent and in combination with azacitidine. Previous studies have demonstrated that Low-Risk (LR) MDS patients with intermittent oral rigosertib treatment at a dose of 560 mg BID  show a transfusion independence rate Show less Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ONTX alerts
Opt-in for
ONTX alerts

from News Quantified
Opt-in for
ONTX alerts

from News Quantified